How to reduce clinical trial site investigator turnover

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/drvarayu)
(Image: Getty/drvarayu)

Related tags: Clinical trial

CTTI has released new recommendations that can be implemented by sponsors, CROs, and others, in order to decrease the number of ‘one and done’ clinical trial site investigators.

The Clinical Trials Transformation Initiative (CTTI) released the recommendations at the Society for Clinical Research Sites (SCRS) Global Site Solutions Summit, which took place last week in Florida.

CTTI was co-founded by Duke University and the US Food and Drug Administration (FDA).

The new recommendations focus on four areas:

  1. Developing site-based research infrastructure and staff
  2. Optimizing trial execution and conduct
  3. Improving site budget and contract negotiations
  4. Discovering additional trials to conduct

Gerrit Hamre, project manager at CTTI said the evidence-based solutions can be implemented across the clinical trial enterprise, including sponsors, contract research organizations (CROs), as well as the site investigators.

By creating a supportive clinical research ecosystem—one that provides adequate infrastructure and staff, continuous training, clear operational and financial procedures, and a climate of mutual respect—investigators will feel more engaged and empowered to continue working in the clinical research space​,” he told Outsourcing-Pharma.com.

A balancing act

Many investigators leave clinical research due to a difficulty balancing workload, time requirements to conduct trials, data and safety reporting burdens, and financial issues, Hamre explained.

However, the professional and personal rewards of conducting research are also evident, and the ability to overcome challenges associated with clinical research is clearly articulated​,” he added.

The goal of the new recommendations is to provide “a roadmap to address these challenges and, ultimately, decrease the number of ‘one and done’ investigators​,” said Hamre.

The project was funded in part by the US FDA grant.

Related news

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Related suppliers

Follow us

Products

View more